Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMpower010 adjuvant atezolizumab versus best supportive care after cisplatin-based chemotherapy in resected non-small cell lung cancer
2023-505981-26-00Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Atezolizumab with Best supportive care (2 arms). Primary endpoint: Disease-free survival. Started Nov 2015; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-505981-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505981-26-00.